Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific, Inc. (TMO) is a global leader in providing science-based solutions, offering a wide range of products and services in the life sciences, analytical instruments, specialty diagnostics, and laboratory products sectors. The company's expansive portfolio includes scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents, serving customers both in the United States and internationally.
Thermo Fisher operates through four distinct segments as of end-2023:
- Analytical Technologies (17% of sales): This segment focuses on providing high-quality instruments and software solutions for various scientific applications.
- Specialty Diagnostic Products (10% of sales): This segment specializes in offering diagnostic reagents and instruments for medical and research laboratories.
- Life Science Solutions (23% of sales): This segment provides reagents, instruments, and consumables used in biological research and drug development.
- Lab Products and Services (54% of sales): This is the largest segment, encompassing laboratory supplies, equipment, and contract research organization (CRO) services.
Thermo Fisher is continually expanding its offerings and capabilities through strategic partnerships, acquisitions, and technological innovation. The company's robust financial performance underscores its leadership in the industry, driven by consistent revenue growth, strong market presence, and a commitment to advancing scientific research and healthcare.
Recent achievements include technological advancements in analytical instruments, enhanced diagnostic solutions, and expanded biopharma services, reflecting Thermo Fisher's dedication to supporting life-saving research and diagnostic processes. Thermo Fisher remains committed to delivering high-quality products and services, fostering scientific breakthroughs, and maintaining its position at the forefront of scientific innovation.
Thermo Fisher Scientific (NYSE: TMO) has announced a 10% increase in its quarterly cash dividend. The company's Board of Directors has authorized a payment of $0.43 per common share, up from the previous $0.39. The dividend will be payable on April 15, 2025, to shareholders of record as of March 14, 2025.
Thermo Fisher Scientific (NYSE:TMO) has announced the election of Karen S. Lynch to its board of directors, effective February 19, 2025. This appointment increases the board's size to 12 members. Lynch, the former president and CEO of CVS Health , brings over three decades of healthcare industry experience. During her tenure at CVS Health, she led more than 300,000 employees and oversaw operations reaching over 120 million consumers through healthcare benefits, pharmacy benefits management, and 9,000+ community health locations.
Lynch's extensive career includes executive positions at Aetna, Magellan Health Services, and Cigna She began her career as a CPA at Ernst & Young LLP and has served on the boards of CVS Health and U.S. Bancorp.
Thermo Fisher Scientific (NYSE: TMO) has announced a 10-year virtual power purchasing agreement (VPPA) with X-ELIO for the Lorca solar project, expected to be operational in early 2026. The company's 73 MW portion will generate approximately 150,000 megawatt-hours of renewable electricity annually, equivalent to powering 40,500 European homes for a year.
This agreement, combined with the previously announced Serbal solar project, will enable TMO to match all its addressable European sites with 100% renewable electricity. The project advances the company's goal of achieving 80% global renewable electricity by 2030. The agreement includes a cohort of pharmaceutical partners (GSK, Gilead Sciences, and Haleon) through the Energize initiative, helping reduce both Scope 2 and Scope 3 emissions.
TMO serves as the cohort lead for this agreement, which aligns with its commitment to reach net-zero emissions by 2050 and its goal to reduce Scope 1 and 2 emissions by 50% by 2030 against a 2018 baseline.
Thermo Fisher Scientific (NYSE: TMO) reported strong Q4 2024 results with revenue growing 5% to $11.40 billion and adjusted EPS increasing 8% to $6.10. Full-year 2024 revenue remained flat at $42.88 billion, while full-year adjusted EPS grew 1% to $21.86.
The company launched several innovative products in 2024, including the Iliad Electron Microscope, Stellar mass spectrometer, and Dionex Inuvion Ion Chromatography system. During Q4, they introduced the iCAP MX Series ICP-MS platform and new additions to the Gibco CTS Detachable Dynabeads platform.
TMO completed the acquisition of Olink and returned $4.6 billion to shareholders through stock buybacks and dividends. The company's Q4 2024 GAAP operating margin improved to 17.7% from 17.0% year-over-year, while adjusted operating margin increased to 23.9% from 23.4%.
Thermo Fisher Scientific (NYSE: TMO) announced that its Olink® Explore Platform has been selected for the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The project aims to analyze over 5,400 proteins from 600,000 samples to discover new protein biomarkers for disease prediction, diagnosis, and treatment.
The project, a collaboration between UK Biobank and 14 leading biopharmaceutical companies, builds on a 2023 pilot project that analyzed 54,000 samples. The study is scheduled to begin in Q1 2025, with data releases starting in 2026 and full dataset availability in 2027. Initially, the project will analyze 300,000 samples, with plans to secure additional funding for another 300,000 samples.
The pilot study's research, published in Nature, has already been cited over 400 times, demonstrating its significant impact on understanding disease development and advancing targeted treatments. One study identified protein risk factors for certain cancers up to seven years before diagnosis.
Thermo Fisher Scientific (NYSE: TMO) has announced that Marc N. Casper, chairman, president and chief executive officer, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 11:15 a.m. (EST). Interested parties can access the webcast through the Investors section of Thermo Fisher's website at www.thermofisher.com.
Thermo Fisher Scientific (NYSE: TMO) has announced it will release its Q4 and full-year 2024 financial results before market opening on Thursday, January 30, 2025. The company will host a conference call at 8:30 a.m. EST to discuss financial performance and future expectations.
Investors can access the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 internationally, using access code 706921. The call will also be available on the company's website investor section. A replay will be accessible through February 14, 2025, under the News, Events & Presentations section.
Thermo Fisher Scientific (NYSE: TMO) has announced the completion of a $1 billion share repurchase program, which resulted in the buyback of 1.9 million shares of its common stock. As of December 3, 2024, the company maintains $3 billion in remaining authorization for future share repurchases.
Thermo Fisher Scientific (NYSE: TMO) announced that its Board of Directors has authorized a new $4 billion share repurchase program. The program, which has no expiration date, will allow the company to buy back shares through open market or negotiated transactions. This new authorization replaces the existing program, which had $1 billion remaining.
Thermo Fisher Scientific (NYSE: TMO) has announced that their chairman, president and CEO Marc N. Casper will deliver a presentation at the Wolfe Healthcare Conference. The presentation is scheduled for Tuesday, November 19, 2024, at 8:00 a.m. EDT. Interested parties can watch the live webcast through the Investors section of Thermo Fisher's website.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
What does Thermo Fisher Scientific, Inc. specialize in?
What are the main segments of Thermo Fisher Scientific?
How much of Thermo Fisher's sales come from Lab Products and Services?
Where does Thermo Fisher Scientific operate?
What recent achievements has Thermo Fisher Scientific made?
What is Thermo Fisher Scientific's stock symbol?
How does Thermo Fisher Scientific support scientific research?
What types of products does Thermo Fisher Scientific offer?
What is Thermo Fisher's commitment to the healthcare industry?
What sets Thermo Fisher Scientific apart in its industry?
